title: Retrospective comparison of chemotherapy-induced myelotoxicity in patients with ovarian cancer under and over 60 years of age.
abstract: We examined whether women aged 60 years or older with ovarian cancer who were treated with surgery and postoperative chemotherapy are at higher risk of developing grade 4 hematological toxicity. Seventy-five patients were included: 34 patients aged < 60 years (group I) were compared with 41 patients aged > or =60 years (group II) after postoperative treatment with single-agent carboplatin or carboplatin/taxane combination chemotherapy. Secondary prophylaxis with granulocyte colony-stimulating factors was performed to avoid dose reduction and chemotherapy delay. A total of 450 chemotherapy cycles was completed. Anemia and thrombocytopenia were mild in both groups. Overall, grade 4 neutropenia developed in 41% (group I) and in 49% (group II) (p=0.51). Febrile neutropenia occurred in 12% and 2%, respectively (p=0.17). The carboplatin/taxane combination was associated with grade 4 neutropenia in 42% (group I) and 58% (group II) (p=0.21). Women > or =60 years are not at higher risk of developing severe myelotoxicity than their younger counterparts, particularly after treatment with carboplatin/taxane combination chemotherapy.
authors.affiliation: Department of Gynecology/Obstetrics, General Hospital Leoben, Austria. florentia.peintinger@lkh-leoben.at
authors.forename: F
authors.initials: F
authors.lastname: Peintinger
authors.forename: A
authors.initials: A
authors.lastname: Georgoulopoulos
authors.forename: G
authors.initials: G
authors.lastname: Ralph
authors.forename: C
authors.initials: C
authors.lastname: Piswanger
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000740:Anemia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D016190:Carboplatin / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006402:Hematologic Diseases / Q000139:chemically induced*; D006801:Humans; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000601:surgery; D011183:Postoperative Complications / Q000188:drug therapy / Q000517:prevention & control*; D011994:Recombinant Proteins; D012189:Retrospective Studies; D012307:Risk Factors; D043823:Taxoids / Q000009:adverse effects* / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D043823:Taxoids; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor; D016190:Carboplatin